ubmslateNT-logo-ubm

NT Mobile Menu

Search form

Topics:

Multiple sclerosis

Multiple sclerosis

The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.

Studies also include stem cell transplantation for treatment-refractory MS and aspirin use for headache to lessen the need for rescue medication.

Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.

Ten general and disease-specific apps for neurologists include assessment scales, anatomical diagrams, and interactive clinical decision support.

February news includes stroke risk with Alzheimer disease & migraine, neonatal hemorrhagic stroke, and head trauma in sports.

Pages

Subscribe to Multiple sclerosis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.